The American Diabetes Association (ADA) has awarded La Jolla Institute (LJI) researcher Stephanie Stanford, Ph.D., a $1.6 million grant to investigate the genetic and environmental factors that trigger the onset of type 1 diabetes.
In a study published yesterday in the scientific journal Nature Immunology, a group at the La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new genes that likely contribute to asthma, a disease that currently affects over 200 million people world wide.
Research toward the world’s first vaccine for heart disease continues to advance at the La Jolla Institute for Allergy and Immunology, with researchers demonstrating significant arterial plaque reduction in concept testing in mice.
A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators from other institutes.
Researchers from the La Jolla Institute for Allergy and Immunology have revealed a critical player in the cellular interactions leading to eczema – a chronic inflammatory skin condition affecting more than 14 million U.S. children and adults.
A major new finding that will significantly advance efforts to create the world’s first antibody-based AIDS vaccine was published today by researchers from the La Jolla Institute for Allergy and Immunology.
La Jolla Institute for Allergy and Immunology has earned the Number 1 ranking in The Scientist magazine’s 2013 “Best Places to Work in Academia” survey of the worldwide academic research community.
La Jolla Institute for Allergy and Immunology and Kyowa Hakko Kirin California, Inc. (KKC), a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (KHK), a global specialty pharmaceutical company, today announced the signing of a new agreement that marks another milestone in one of the most enduring industry-academic collaborations in the world.
Herbert A. Wertheim, O.D., D.Sc., M.D. (hc), a noted inventor, philanthropist, and optometric and visual science industry pioneer, has been elected to La Jolla Institute for Allergy and Immunology’s Board of Directors.
A major study from researchers at the La Jolla Institute for Allergy and Immunology provides new revelations about the intricate pathways involved in turning on T cells, the body’s most important disease-fighting cells, and was published today in the prestigious scientific journal Nature. The La Jolla Institute team is the first to prove that a certain type of protein, called septins, play an essential role in T cell activation.
Seeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase II of a clinical trial to investigate a potential new therapy for reducing the disorder’s severest symptoms. More than 100,000 Americans and several million people worldwide suffer from this genetic disorder.
As efforts to create a strong and effective vaccine for the dreaded dengue virus continue to hit snags, a new study from researchers at the La Jolla Institute for Allergy & Immunology offers surprising evidence that suggests the need for a revamped approach to dengue vaccine design. The finding runs counter to current scientific understanding of the key cells that need to be induced to develop a successful dengue vaccine.
A virus most people probably have never heard of, but that the majority of us carry, is the No. 1 infectious cause of congenital birth defects in the U.S. today. Because of cytomegalovirus (CMV) infection, 1 in 750 children are born with or develop permanent disabilities. But efforts to develop a CMV vaccine are gaining ground. Researchers from the La Jolla Institute and Cardiff University have discovered a cellular mechanism that could prove critical in creating a CMV vaccine.
A research team led by the La Jolla Institute for Allergy & Immunology has discovered the mechanism that enables CD4 helper T cells to assume the more aggressive role of killer T cells in mounting an immune attack against viruses, cancerous tumors and other damaged or infected cells. The finding, made in collaboration with researchers from the RIKEN Institute in Japan, could enable the development of more potent drugs for AIDS, cancer and many other diseases based on using this mechanism to trigger larger armies of killer T cells against infected or damaged cells.
The ability to “see the forest for the trees” is a powerful concept in this age of information overload, a factor acutely evident in the research field, where thousands of scientific discoveries are published each year. But thanks to a major federal contract renewal and the inventive minds at the La Jolla Institute for Allergy & Immunology, researchers around the world will soon have an enhanced resource for mining precious information nuggets critical to combating infectious diseases, autoimmune diseases, allergies and other immune-mediated diseases.
Researchers at the La Jolla Institute for Allergy & Immunology have identified the specific type of immune cells (CD4 T cells) that orchestrate the inflammatory attack on the artery wall, which is a major contributor to plaque buildup in heart disease. Further, the researchers discovered that these immune cells are launching their attack in response to normal proteins that the body mistakes as being foreign, an autoimmune type response, which points up the possibility of developing a tolerogenic vaccine for heart disease.
Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule’s previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.
Like detectives seeking footprints and other clues on a television “whodunit,” science can also benefit from analyzing the tracks of important players in the body’s molecular landscape. Klaus Ley, M.D., a scientist at the La Jolla Institute for Allergy & Immunology, has done just that and illuminated a key step in the journey of inflammation-producing immune cells. The finding provides powerful, previously unknown information about critical biological mechanisms underlying heart disease and many other disorders.
Shane Crotty, Ph.D., a scientist at the La Jolla Institute for Allergy & Immunology, has been selected for the prestigious Biosciences Investigator Award in recognition of his groundbreaking work in vaccine research. The award is presented annually by the American Association of Immunologists (AAI) and recognizes early-career investigators for outstanding research contributions to the field of immunology.
Adverse drug reactions are a major issue that cause harm, are costly and restrict treatment options for patients and the development of new drugs. A groundbreaking finding by researchers from the La Jolla Institute for Allergy & Immunology could lead to a new way to dramatically improve drug safety by identifying drugs at risk to cause potentially fatal genetic-linked hypersensitivity reactions before their use in man.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right